2-{(2R)-1-[(3,4-dichlorophenyl)sulfonyl]-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl}-N-{2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl}acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-{(2R)-1-[(3,4-dichlorophenyl)sulfonyl]-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl}-N-{2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl}acetamide
• 英文别名: 2-{1-[(2R)-(3,4-dichlorophenyl)sulfonyl]-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl}-N-{-2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl}acetamide；2-{1-[(2R)-(3,4-dichlorophenyl)sulfonyl]-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl}-N-{2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl}acetamide；2-[1-(3,4-dichloro-benzenesulfonyl)-3-oxo-1,2,3,4-tetrahydro-quinoxalin-2-yl]-N-{2-[4-(4,5-dihydro-1H-imidazol-2-yl)-phenyl]-ethyl}-acetamide；2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)-；2-[(2R)-1-(3,4-dichlorophenyl)sulfonyl-3-oxo-2,4-dihydroquinoxalin-2-yl]-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]acetamide
• 化学式: C₂₇H₂₅Cl₂N₅O₄S
• 分子量: 586.499
• InChiKey: HYJYRDCPGUEYND-XMMPIXPASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  39
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  128
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-(2-叠氮乙基)苯甲腈 在 palladium on activated charcoal 盐酸 、 N-羟基-7-氮杂苯并三氮唑 、 氢气 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 2.0h， 生成 2-{(2R)-1-[(3,4-dichlorophenyl)sulfonyl]-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl}-N-{2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl}acetamide
  参考文献：
  名称：

  2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds

  摘要：

  2-喹喔啉酮衍生物是布雷金肽B1拮抗剂或逆向激动剂，可用于治疗或预防与布雷金肽B1途径相关的症状，如疼痛和炎症。

  公开号：

  US20050020591A1

文献信息

• [EN] NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS<br/>[FR] NOUVEAUX DERIVES DE QUINOXALINONE CONSTITUANT DES ANTAGONISTES B1 DE LA BRADYKININE
  申请人：MERCK & CO INC

  公开号：WO2004054584A1

  公开（公告）日：2004-07-01

  2-Quinoxalinone derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

  2-喹啉酮衍生物是布雷金肽B1拮抗剂或逆向激动剂，在治疗或预防与布雷金肽B1途径相关的疼痛和炎症症状方面具有用处。
• Novel quinoxalinone derivatives as bradykinin B1 antagonists
  申请人：——

  公开号：US20040132733A1

  公开（公告）日：2004-07-08

  2-Quinoxalinone derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

  2-喹喔啉酮衍生物是布雷金肽B1拮抗剂或逆向激动剂，可用于治疗或预防与布雷金肽B1途径相关的疼痛和炎症等症状。
• Discovery of a Potent, Non-peptide Bradykinin B₁ Receptor Antagonist
  作者：Dai-Shi Su、M. Kristine Markowitz、Robert M. DiPardo、Kathy L. Murphy、C. Meacham Harrell、Stacy S. O'Malley、Richard W. Ransom、Raymond S. L. Chang、Sookhee Ha、Fred J. Hess、Douglas J. Pettibone、Glenn S. Mason、Susan Boyce、Roger M. Freidinger、Mark G. Bock

  DOI：10.1021/ja0353457

  日期：2003.6.1

  Bradykinin (BK) plays an important role in the pathophysiological processes accompanying pain and inflammation. Selective bradykinin B1 receptor antagonists have been shown to be anti-nociceptive in animal models and could be novel therapeutic agents for the treatment of pain and inflammation. We have explored chemical modifications in a series of dihydroquinoxalinone sulfonamides to evaluate the effects of various structural changes on biological activity. The optimization of a screening lead compound, facilitated by a homology model of the BK B1 receptor, culminated in the discovery of a potent human BK B1 receptor antagonist. Results from site-directed mutagenesis studies and experiments in an animal pain model are presented.
• NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS
  申请人：Merck & Co., Inc.

  公开号：EP1572209A1

  公开（公告）日：2005-09-14
• EP1572209A4
  申请人：——

  公开号：EP1572209A4

  公开（公告）日：2006-12-06